Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference By: Arcus Biosciences via Business Wire May 30, 2023 at 16:00 PM EDT Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. The fireside chat will take place on Tuesday, June 13th, 2023 at 4 p.m. PT. A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005001/en/Contacts Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference By: Arcus Biosciences via Business Wire May 30, 2023 at 16:00 PM EDT Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. The fireside chat will take place on Tuesday, June 13th, 2023 at 4 p.m. PT. A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005001/en/Contacts Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. The fireside chat will take place on Tuesday, June 13th, 2023 at 4 p.m. PT. A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter. View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005001/en/
Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 hkolkey@arcusbio.com Investor Inquiries Pia Banerjee Head of Investor Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com